EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies

Gaetano Scotto iD, Vincenzina Fazio, Ali Muhammed Moula, Sri Charan Bindu Bavisetty, Alessia Franza, Salvatore Massa iD

Pathogens · 20.04.2026 · 15 (4) · 443

DOI: 10.3390/pathogens15040443 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 20.04.2026. Verfasst von Gaetano Scotto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Foggia, 71121 Foggia, Italy. Hauptthemen laut MEDLINE: Nipah Virus, Henipavirus Infections, Encephalitis, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus responsible for sporadic outbreaks of severe disease with high case fatality rates in South and Southeast Asia. Human infection occurs through spillover from natural reservoirs, primarily fruit bats, or via human-to-human transmission, and is characterized by a broad clinical spectrum ranging from asymptomatic infection to acute respiratory disease and fatal encephalitis. Following entry via ephrin-B2 and ephrin-B3 receptors, NiV exhibits marked endothelial and neuronal tropism, leading to systemic vasculitis, disruption of the blood–brain barrier, and direct infection of the central nervous system. Disease progression is driven by a complex interplay between viral replication strategies and host immune responses. NiV effectively counteracts innate immunity through multiple viral proteins that inhibit interferon signaling, while simultaneously inducing dysregulated inflammatory responses that contribute to tissue damage and multi-organ failure. Neurological involvement represents the most severe manifestation, often resulting in acute or relapsing encephalitis with long-term sequelae among survivors. Despite the severity of the disease, no licensed antiviral therapies or human vaccines are currently available. Therapeutic development has focused on neutralizing monoclonal antibodies targeting viral glycoproteins and small-molecule antivirals that inhibit viral RNA synthesis, both of which show promising results in preclinical models, but remain limited by timing and translational challenges. In parallel, several vaccine platforms—including viral vectors, mRNA-based constructs, and recombinant protein subunits—have advanced to early-phase clinical trials, demonstrating encouraging immunogenicity. Beyond biomedical interventions, effective outbreak containment relies on integrated public health strategies. The “Kerala model” highlights the importance of rapid case identification, isolation, contact tracing, and community engagement within a One Health framework to mitigate transmission and reduce mortality. This review synthesizes the current knowledge on NiV pathogenesis, immune evasion, clinical manifestations, and emerging therapeutic and vaccine strategies, while highlighting critical gaps and future directions for improving the preparedness and response to this high-consequence emerging pathogen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nipah VirusHenipavirus InfectionsEncephalitis, ViralHumansAnimalsAntiviral Agents

Stichwörter der Autor:innen

Nipah virusencephalitismonoclonal antibodiesneuropathogenesispulmonary involvementrespiratory diseasevaccine developmentzoonotic virus

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Foggia, 71121 Foggia, Italy.
  • Department of Life Sciences, School of Science, Gandhi Institute of Technology and Management (GITAM) University, Hyderabad 502329, India.
  • Faculty of Food Industry, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand.
  • Department of Agricultural, Food and Environmental Sciences, University of Foggia, 71121 Foggia, Italy.

ORCID-Profile: Gaetano Scotto, Salvatore Massa

Zitieren

APA

Scotto, G., Fazio, V., Moula, A. M., Bavisetty, S. C. B., Franza, A., & Massa, S. (2026). Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies. Pathogens, 15(4), 443. https://doi.org/10.3390/pathogens15040443

Vancouver

Scotto G, Fazio V, Moula AM, Bavisetty SCB, Franza A, Massa S. Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies. Pathogens. 2026;15(4):443. doi:10.3390/pathogens15040443

BibTeX
@article{Scotto2026,
  author = {Scotto, Gaetano and Fazio, Vincenzina and Moula, Ali Muhammed and Bavisetty, Sri Charan Bindu and Franza, Alessia and Massa, Salvatore},
  title = {Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {443},
  doi = {10.3390/pathogens15040443}
}
Kostenlos starten →